Open AccessProlonged survival in patients with hand-foot skin reaction secondary to cooperative sorafenib treatment
Author(s) -
Masanori Ochi,
Toshiro Kamoshida,
Masahiro Araki,
Tadashi Ikegami
Publication year - 2021
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v27.i32.5424
Subject(s) - sorafenib , medicine , foot (prosody) , skin reaction , surgery , oncology , dermatology , hepatocellular carcinoma , philosophy , linguistics
Sorafenib is an oral drug that prolongs overall survival (OS) in patients with hepatocellular carcinoma. Adverse events, including hand-foot skin reaction (HFSR), lead to permanent sorafenib discontinuation.